Cutia Therapeutics (HKG:2487)
Hong Kong · Delayed Price · Currency is HKD 1.190
-0.010 (-0.83%)
Sep 21, 2026, 10:52 AM HKT
Cutia Therapeutics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 332.58 | 336.15 | 279.62 | 137.62 | 11.37 | 2.04 | |
Revenue Growth | 32.86% | 20.22% | 103.17% | 1110.83% | 457.70% | - |
Cost of Revenue | 154.34 | 140.36 | 136.15 | 66.62 | 3.43 | 0.43 |
Gross Profit | 178.24 | 195.79 | 143.46 | 71.01 | 7.94 | 1.61 |
Selling, General & Admin | 296.38 | 347.29 | 405.53 | 394.2 | 136.39 | 71.04 |
Research & Development | 122.93 | 148.65 | 199.05 | 215.71 | 180.76 | 110.56 |
Operating Expenses | 424.49 | 504.4 | 605.01 | 610.66 | 317.14 | 181.6 |
Operating Income | -246.25 | -308.61 | -461.54 | -539.65 | -309.2 | -179.99 |
Interest Expense | -8.98 | -9.71 | -10.86 | -4.48 | -1.73 | -0.56 |
Interest & Investment Income | 6 | 6.53 | 11.81 | 23.41 | 17.37 | 6.11 |
Currency Exchange Gain (Loss) | -4.01 | -4.01 | 2.34 | 20.8 | 73.98 | -23.03 |
Other Non Operating Income (Expenses) | -20.46 | -24.24 | 3.32 | -11.82 | -16.83 | 3.4 |
EBT Excluding Unusual Items | -273.7 | -340.04 | -454.93 | -511.74 | -236.41 | -194.06 |
Gain (Loss) on Sale of Investments | -3.34 | 1.51 | 21.99 | 2.47 | 7.68 | -5.2 |
Gain (Loss) on Sale of Assets | -0.97 | -0.97 | -0.36 | -0.25 | - | - |
Other Unusual Items | -0.69 | -0.69 | -0.51 | -1,454 | -327.1 | -120.33 |
Pretax Income | -278.71 | -340.19 | -433.81 | -1,964 | -555.84 | -319.58 |
Net Income | -281.2 | -340.19 | -433.81 | -1,964 | -555.84 | -319.58 |
Net Income to Common | -281.2 | -340.19 | -433.81 | -1,964 | -555.84 | -319.58 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 353 | 331 | 307 | 205 | 80 | 80 |
Shares Outstanding (Diluted) | 353 | 331 | 307 | 205 | 80 | 80 |
Shares Change | 12.39% | 7.70% | 50.13% | 155.62% | - | - |
EPS (Basic) | -0.80 | -1.03 | -1.41 | -9.60 | -6.94 | -3.99 |
EPS (Diluted) | -0.80 | -1.03 | -1.41 | -9.60 | -6.94 | -3.99 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -301.79 | -465.56 | -437.04 | -370.54 | -184.2 |
Free Cash Flow Per Share | - | -0.91 | -1.52 | -2.14 | -4.63 | -2.30 |
Gross Margin | 53.59% | 58.25% | 51.31% | 51.60% | 69.84% | 79.00% |
Operating Margin | -74.04% | -91.81% | -165.06% | -392.13% | -2720.43% | -8831.45% |
Profit Margin | -84.55% | -101.20% | -155.15% | -1426.91% | -4890.34% | -15681.11% |
Free Cash Flow Margin | - | -89.78% | -166.50% | -317.56% | -3260.10% | -9038.08% |
EBITDA | -216.44 | -277.93 | -432.92 | -508.8 | -298.43 | -174.06 |
EBITDA Margin | -65.08% | -82.68% | -154.83% | - | - | - |
D&A For EBITDA | 29.81 | 30.68 | 28.62 | 30.85 | 10.78 | 5.93 |
EBIT | -246.25 | -308.61 | -461.54 | -539.65 | -309.2 | -179.99 |
EBIT Margin | -74.04% | -91.81% | -165.06% | - | - | - |